Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.
Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...
With AI advancements upending the role of senior executives, the question is what the C-suite transformation should look like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback